{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:53:37Z","timestamp":1783119217639,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T00:00:00Z","timestamp":1517011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11255-018-1793-1","type":"journal-article","created":{"date-parts":[[2018,1,27]],"date-time":"2018-01-27T09:14:20Z","timestamp":1517044460000},"page":"419-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of renal stone formation in patients treated with luteinising hormone-releasing hormone analogues for prostate cancer: importance of bone metabolism and urine calcium"],"prefix":"10.1007","volume":"50","author":[{"given":"Enrique","family":"Diaz-Convalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Arrabal-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Cano-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Dominguez-Amillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Canales-Casco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Arrabal-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,27]]},"reference":[{"issue":"Suppl 5","key":"1793_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bju.12964","volume":"115","author":"H Rhee","year":"2015","unstructured":"Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM et al (2015) Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int 115(Suppl 5):3\u201313","journal-title":"BJU Int"},{"key":"1793_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM et al (2016) Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2:453\u2013461","journal-title":"JAMA Oncol"},{"key":"1793_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/pcan.2016.25","volume":"19","author":"JL Kiwata","year":"2016","unstructured":"Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM (2016) A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis 19:323\u2013332","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1793_CR4","doi-asserted-by":"publisher","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","volume":"10","author":"C Bosco","year":"2015","unstructured":"Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M (2015) Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS ONE 10:e0117344","journal-title":"PLoS ONE"},{"key":"1793_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/MOU.0000000000000111","volume":"24","author":"MA Arrabal-Polo","year":"2014","unstructured":"Arrabal-Polo MA, Cano-Garc\u00eda Mdel C, Canales BK, Arrabal-Mart\u00edn M (2014) Calcium nephrolithiasis and bone demineralization: pathophysiology, diagnosis, and medical management. Curr Opin Urol 24:633\u2013638","journal-title":"Curr Opin Urol"},{"key":"1793_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000427","author":"DA Wollin","year":"2017","unstructured":"Wollin DA, Skolarikos A, Preminger GM (2017) Obesity and metabolic stone disease. Curr Opin Urol. https:\/\/doi.org\/10.1097\/MOU.0000000000000427","journal-title":"Curr Opin Urol"},{"key":"1793_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bju.13307","volume":"117","author":"G Morgia","year":"2016","unstructured":"Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P et al (2016) Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU Int 117:867\u2013873","journal-title":"BJU Int"},{"key":"1793_CR8","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.2337\/db13-1505","volume":"63","author":"IC Yu","year":"2014","unstructured":"Yu IC, Lin HY, Sparks JD, Yeh S, Chang C (2014) Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 63:3180\u20133188","journal-title":"Diabetes"},{"key":"1793_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.rpor.2015.06.004","volume":"20","author":"PM Samper Ots","year":"2015","unstructured":"Samper Ots PM, Mu\u00f1oz Garc\u00eda JL, R\u00edos Kavadoy Y, Couselo Paniagua ML, Villafranca Iturre E, Rodr\u00edguez Li\u00f1\u00e1n M et al (2015) SIMBOSPROST: prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: a multicentre, cross-sectional study. Rep Pract Oncol Radiother 20:370\u2013376","journal-title":"Rep Pract Oncol Radiother"},{"key":"1793_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pros.21047","volume":"70","author":"E Isahaya","year":"2010","unstructured":"Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K (2010) Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone\/insulin-like growth factor-1\/parathyroid hormone axis. Prostate 70:155\u2013161","journal-title":"Prostate"},{"key":"1793_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.acuro.2012.10.003","volume":"37","author":"M\u00c1 Arrabal-Polo","year":"2013","unstructured":"Arrabal-Polo M\u00c1, Sierra Gir\u00f3n-Prieto M, Orgaz-Molina J, Zuluaga-G\u00f3mez A, Arias-Santiago S, Arrabal-Mart\u00edn M (2013) Calcium renal lithiasis and bone mineral density. Importance of bone metabolism in urinary lithiasis. Actas Urol Esp 37:362\u2013367","journal-title":"Actas Urol Esp"},{"key":"1793_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1111\/j.1464-410X.2011.10167.x","volume":"108","author":"MA Arrabal-Polo","year":"2011","unstructured":"Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, Lopez-Leon VM, Merino-Salas S, Ochoa-Hortal MA et al (2011) Mineral density and bone remodelling markers in patients with calcium lithiasis. BJU Int 108:1903\u20131908","journal-title":"BJU Int"},{"key":"1793_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","volume":"111","author":"YH Shao","year":"2013","unstructured":"Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 111:745\u2013752","journal-title":"BJU Int"},{"key":"1793_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertov\u00e1 Z, Brown C, Karunasinghe N, Bishop K, Ferguson L et al (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837","journal-title":"BMC Cancer"},{"key":"1793_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2215\/CJN.06030614","volume":"10","author":"L Shavit","year":"2015","unstructured":"Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro PM, Moochhala SH et al (2015) Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol 10:278\u2013285","journal-title":"Clin J Am Soc Nephrol"},{"key":"1793_CR16","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00198-016-3658-8","volume":"27","author":"P Lucato","year":"2016","unstructured":"Lucato P, Trevisan C, Stubbs B, Zanforlini BM, Solmi M, Luchini C et al (2016) Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis. Osteoporos Int 27:3155\u20133164","journal-title":"Osteoporos Int"},{"key":"1793_CR17","doi-asserted-by":"publisher","first-page":"39562","DOI":"10.1038\/srep39562","volume":"7","author":"SH Kim","year":"2017","unstructured":"Kim SH, Joung JY, Kim S, Rha KH, Kim HG, Kwak C et al (2017) Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: a 12\u00a0month-prospective observational study. Sci Rep 7:39562","journal-title":"Sci Rep"},{"key":"1793_CR18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.14310\/horm.2002.1628","volume":"14","author":"M\u00c1 Arrabal-Polo","year":"2015","unstructured":"Arrabal-Polo M\u00c1, Cano-Garc\u00eda Mdel C, Arrabal-Mart\u00edn M (2015) \u0392ones, stones and androgen deprivation therapy. Hormones (Athens) 14:668\u2013669","journal-title":"Hormones (Athens)"},{"key":"1793_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.medcli.2017.01.021","volume":"148","author":"EJ D\u00edaz Conval\u00eda","year":"2017","unstructured":"D\u00edaz Conval\u00eda EJ, Cano-Garc\u00eda MDC, Mij\u00e1n-Ortiz JL, Arrabal-Mart\u00edn M, Arrabal-Polo M\u00c1, C\u00f3zar-Olmo JM (2017) Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: results of a case-control study. Med Clin (Barc) 148:495\u2013497","journal-title":"Med Clin (Barc)"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-1793-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:13:04Z","timestamp":1751245984000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-1793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,27]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-1793-1","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,27]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Good Clinical Practice guidelines have been put into practice and followed, as well as those of the Helsinki Declaration in its latest version (Fortaleza, Brazil). The patients have received a detailed information sheet about the study and have voluntarily and consciously signed the consent to participate in the study. This study forms part of a research study for a doctoral thesis enrolled in the University of Granada (Spain), within the PhD program of Clinical Medicine and Public Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}